Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors

No abstract is available for this paper.

• Publication year

  2017

• Venue

  New England Journal of Medicine

• Publication date

  2017-01-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1607427PMID 28076709PMCID PMC5895095
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site

  2016cited by this paper
• Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate

  2016cited by this paper
• Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

  2016cited by this paper
• Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.

  2016cited by this paper
• Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer.

  2016cited by this paper
• Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course

  2015cited by this paper
• Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

  2014cited by this paper
• GEPNETs update: Radionuclide therapy in neuroendocrine tumors.

  2014cited by this paper
• Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours

  2014cited by this paper
• Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

  2014cited by this paper
• Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors: The First US Phase 2 Experience

  2014cited by this paper
• Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors.

  2013cited by this paper
• Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate

  2013cited by this paper
• Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

  2012cited by this paper
• Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.

  2011cited by this paper
• Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

  2011cited by this paper
• Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.

  2011cited by this paper
• Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study

  2011cited by this paper
• Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

  2009cited by this paper
• One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

  2008cited by this paper
• Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

  2008cited by this paper
• Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.

  2006cited by this paper
• Carcinoid Tumors

  2006cited by this paper
• A 5‐decade analysis of 13,715 carcinoid tumors

  2003cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.

  1999cited by this paper
• Carcinoid tumors.

  1999cited by this paper
• Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history.

  1994cited by this paper
• Radiotherapy with a Radiolabeled Somatostatin Analogue, [111In‐DTPA‐d‐Phe1]‐Octreotide

  1994cited by this paper
• Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.

  1993cited by this paper
• Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

  1993cited by this paper
• Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.

  1986cited by this paper

• CopperNostics-Here We Are Now, Entertain Us!

  2026cites this paper
• Receptor-targeted technetium-99m radiopharmaceuticals: increasing access to molecular imaging in healthcare

  2026cites this paper
• Multicenter Comparison of Radionuclide Calibrators and SPECT/CT Protocols for Quantitative 177Lu Imaging in Clinical Practice

  2026cites this paper
• Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [¹⁷⁷Lu]Lu-DOTA-TATE.

  2026cites this paper
• Harnessing Frémy's salt for tyrosine-directed bioconjugations

  2026cites this paper
• Effect of Structural Alteration in Albumin Binder Moiety on Tumor Accumulation of Somatostatin Receptor 2‑Targeted Radioligands.

  2026cites this paper
• Resection of the primary tumor with or without liver resection reduces the risk of death in patients with liver metastatic gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis

  2026cites this paper
• The impact of radioligand therapy on prognosis in patients with lung neuroendocrine tumors

  2026cites this paper
• Lesion-level dual-tracer PET biomarkers predict prognosis in multiple myeloma treated with CXCR4-directed radiopharmaceutical therapy.

  2026cites this paper
• Emerging Theranostic Targets in Squamous Cell Carcinoma of the Head and Neck

  2026cites this paper
• From uniform to heterogeneous dose models: connecting cellular and tumor absorbed dose-response for [177Lu]Lu-DOTATATE and [161Tb]Tb-DOTATATE.

  2026cites this paper
• Contemporary opportunities and potential of Auger electron-emitting theranostics

  2026cites this paper
• A case of renal primary neuroendocrine tumor (G3) in which 177Lu-PRRT was effective for disease control

  2026cites this paper
• Lead radionuclides for theranostic applications in nuclear medicine: from atom to bedside

  2026cites this paper
• Fully Automated [18F]AlF Radiolabeling Using a Microdroplet Reactor Platform.

  2026cites this paper
• Management of Peptide Receptor Radionuclide Therapy Toxicities in Neuroendocrine Neoplasm Patients

  2026influential citation
• Preclinical Study of CDH3-Targeted 89Zr/177Lu Theranostics in Triple-Negative Breast Cancer

  2026cites this paper
• Gastroenteropancreatic neuroendocrine neoplasms in children and adults: a comparative review

  2026cites this paper
• Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study.

  2026cites this paper
• Responses to medical treatment in patients with metastatic unresectable small intestinal neuroendocrine tumors – A single center study of 378 patients

  2026influential citation
• Established and Emerging Therapies for High-Risk Neuroblastoma.

  2026cites this paper
• Oxalate nephropathy from untreated pancreatic insufficiency in a neuroendocrine tumour patient

  2026cites this paper
• Strategies to control the geometry and symmetry around lanthanide centres for tailored luminescence and magnetism.

  2026cites this paper
• Multivalvular Cardiac Involvement from Giant Hepatic Metastases of an Ileal Neuroendocrine Tumor

  2026cites this paper
• Tangeretin Suppresses LUAD via SSTR4 Downregulation: Integrated Bioinformatics and Functional Validation

  2026cites this paper
• Future Directions and Emerging Approaches in the Treatment of Brain Metastases.

  2026cites this paper
• Real-Time Imaging of 177Lu-Labeled Radiopharmaceutical Infusions with a Portable γ-Camera: Pilot Trial Results

  2026cites this paper
• Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody-Drug conjugates.

  2026cites this paper
• Prognostic implications of [¹⁸F]FDG PET and metabolic changes in patients with advanced metastatic neuroendocrine tumors undergoing rechallenge PRRT: final results from a multicenter 10-year survival WARMTH study

  2026cites this paper
• Intra-arterial peptide receptor radionuclide therapy (IA-PRRT) in patients with SSTR-expressing neuroendocrine neoplasms: short- and long-term safety and efficacy for up to 13 years

  2026cites this paper
• Recent advances in coordination chemistry on the application and development of radiopharmaceuticals and boron neutron capture therapy

  2026cites this paper
• Peptide receptor radionuclide therapy (PRRT) in high grade neuroendocrine neoplasms: a systematic review and meta-analysis.

  2026cites this paper
• Surgery for Gastroenteropancreatic Neuroendocrine Tumors with Synchronous Liver Metastasis.

  2026cites this paper
• Predicting eligibility for outpatient 177Lu-DOTATATE-targeted radionuclide therapy in patients with neuroendocrine tumors.

  2026cites this paper
• Radioligand Therapy in Meningiomas: Today’s Evidence, Tomorrow’s Possibilities

  2026cites this paper
• A case report of enduring benefit of sequential PRRT in malignant insulinoma

  2026cites this paper
• Chronic Hematologic Toxicity After Peptide Receptor Radionuclide Therapy: An Underrecognized Challenge in Neuroendocrine Tumors

  2026cites this paper
• Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung Cancer

  2026cites this paper
• Recommendations for the dosimetry of patients undergoing therapy with radiopharmaceuticals that include 177Lu.

  2026cites this paper
• Global insights into [177Lu]Lu-DOTATATE safety: a comprehensive disproportionality analysis from the WHO pharmacovigilance database.

  2026cites this paper
• Cost-effectiveness of cabozantinib versus placebo for advanced neuroendocrine tumors from crossover-adjusted analysis in the United States and China.

  2026cites this paper
• Radiotheranostics in an evolving landscape: Emerging themes and considerations from a radiation therapy perspective.

  2026cites this paper
• Challenges to the management of oncologic theranostics clinical trials: recommendations for the conduct of theranostics trials at investigational sites

  2026cites this paper
• Medical Management of Well-Differentiated Pancreatic Neuroendocrine Tumors: From Conventional Therapies to Emerging Strategies

  2026cites this paper
• Current Interventional Radiology Strategies for Liver Metastases

  2026cites this paper
• Low Radioactivity Levels in Blood Samples After Targeted Radionuclide Therapy: Minimal Radiation Exposure of Healthcare Staff

  2026cites this paper
• Evaluation of Reduced Single-Photon Emission Computed Tomography Imaging Protocols and Software Variability in 177Lu-DOTATATE Dosimetry: Protocol for an Exploratory Observational Trial.

  2026cites this paper
• Safety and efficacy of peptide receptor radionuclide therapy for advanced medullary thyroid cancer: a systematic review and meta-analysis

  2026influential citation
• Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions.

  2026cites this paper
• Tumor Targeting with Peptide-Drug Conjugates: Showcasing Key Progress and Hurdles.

  2026cites this paper
• Clinical Dosimetry Models and Pathway to Integration in Routine Nuclear Medicine Practice.

  2026cites this paper
• Recent Advances in the Management of Pancreatic Neuroendocrine Tumors: From Diagnosis, Treatment to Biology.

  2026cites this paper
• Advancing precision tumor therapy: Progress in targeted delivery of peptide-based nanomaterials from microenvironment to organelles

  2026cites this paper
• Somatostatin receptor expression for peptide receptor radionuclide therapy in Japanese patients with recurrent or metastatic differentiated thyroid cancer.

  2026cites this paper
• Head-to-Head Comparison of [68Ga]Ga-DOTATATE PET/CT and [68Ga]Ga-NODAGA-LM3 PET/CT.

  2026cites this paper
• Evaluation of Daughter Radionuclide Release from the 103Pd/103mRh In Vivo Generator for Targeted Auger Therapy

  2026cites this paper
• Selecting optimal therapy for advanced non-functional pancreatic neuroendocrine tumors: latest research and therapeutic advances

  2025influential citation
• Advances in Non-Surgical Management of Neuroendocrine Neoplasms

  2025cites this paper
• Multicycle Dosimetric Behavior and Dose–Effect Relationships in [177Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy

  2025cites this paper
• PRRT plus holmium‐166‐SIRT (HEPAR PLuS) versus PRRT‐only in patients with metastatic neuroendocrine tumors: A propensity‐score matched analysis

  2025cites this paper
• Nuclear Nanomedicines: Utilization of Radiolabelling Strategies, Drug Formulation, Delivery, and Regulatory Aspects for Disease Management.

  2025cites this paper
• CD70-Targeted [18F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal Carcinoma: A Proof-of-Concept Study

  2025cites this paper
• Upfront Oxaliplatin–Fluoropyrimidine Chemotherapy and Somatostatin Analogues in Advanced Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors

  2025cites this paper
• Peptide-based drugs in immunotherapy: current advances and future prospects

  2025cites this paper
• Modern approaches in neuroendocrine tumors (NETs).

  2025cites this paper
• Relationship Between Best Tumor Shrinkage and Progression‐Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [ 177Lu]Lu‐DOTA‐TATE: Ad Hoc Analysis of the Phase III NETTER‐1 Trial

  2025cites this paper
• Dual-enzyme activated theranostic nanoparticles for image-guided glioblastoma therapy

  2025cites this paper
• Novel dibutyl ether resin for the purification of the Auger emitter antimony-119 from tin targets.

  2025cites this paper
• [1. Development and Clinical Application Prospects of Nuclear Medicine Therapy].

  2025cites this paper
• Predicting [177Lu]Lu‐DOTA‐TATE dosimetry by using pre‐therapy [68Ga]Ga‐DOTA‐TATE PET/CT and biomarkers in patient with neuroendocrine tumors

  2025cites this paper
• Quantitative 177Lu-DOTATATE SPECT/CT is predictive of 6-month PRRT morphological response in midgut neuroendocrine tumors: a pilot study

  2025cites this paper
• Case of the Season: 177Lu-DOTATATE Peptide Receptor Radiotherapy With Acute Dialysis Support in a Patient With Chronic Kidney Disease (CKD).

  2025cites this paper
• Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology.

  2025cites this paper
• Pre-treatment 111In-pentetreotide SPECT/CT vs. baseline 177Lu-DOTATATE SPECT/CT: are there differences in lesion uptake and detectability?

  2025influential citation
• Mesenteric Fibrosis in Neuroendocrine Neoplasms: a Systematic Review of New Thoughts on Causation and Potential Treatments

  2025cites this paper
• Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during 177Lu/225Ac treatment in neuroendocrine tumors and metastatic prostate cancer

  2025cites this paper
• Patient-Specific Dosimetry-Driven PRRT: Time to Move Forward!

  2025cites this paper
• Stellenwert der Peptid-Radio-Rezeptor-Therapie für das Management neuroendokriner Tumoren

  2025cites this paper
• Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study

  2025influential citation
• Dual-targeted alpha therapy mitigates prostate cancer and boosts immune checkpoint blockade therapy.

  2025cites this paper
• Neuroendocrine Tumors: Beta Labeled Radiopeptides.

  2025cites this paper
• Beyond fluorodeoxyglucose: Molecular imaging of cancer in precision medicine

  2025cites this paper
• PANCREATIC NEUROENDOCRINE NEOPLASMS (pNENs): GENETIC AND ENVIRONMENTAL BIOMARKERS FOR RISK OF OCCURRENCE AND PROGNOSIS.

  2025cites this paper
• Upregulation of SSTR2 Expression and Radioligand Binding of [18F]SiTATE in Neuroendocrine Tumour Cells with Combined Inhibition of Class I HDACs and LSD1

  2025cites this paper
• Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis

  2025cites this paper
• Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving peptide receptor radionuclide therapy

  2025cites this paper
• Patent spotlight on theranostics targeting fibroblast activation protein for personalized cancer care

  2025cites this paper
• Assessment of [177Lu]Lu-DOTATATE Dosimetry from High-Speed Whole-Body Recordings Provided by a 360° Cadmium–Zinc–Telluride Camera Compared with Results from a Conventional Anger-Camera Protocol

  2025cites this paper
• Determining PSMA-617 Mass and Molar Activity in Pluvicto Doses

  2025cites this paper
• Análisis de variables dosimétricas y clínicas en el tratamiento de los tumores neuroendocrinos con [177Lu]Lu-DOTA-TATE

  2025cites this paper
• The neuroscience of cancer: Focus on neuropeptidergic systems

  2025cites this paper
• Characterizing SSTR2 expression and modulation for targeted imaging and therapy in preclinical models of triple-negative breast cancer

  2025cites this paper
• Eastern Canadian Gastrointestinal Cancer Consensus Conference 2024

  2025cites this paper
• Efficacy and Safety of Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis of Comparative Studies

  2025cites this paper
• The Potential of Peptide-Based Inhibitors in Disrupting Protein–Protein Interactions for Targeted Cancer Therapy

  2025cites this paper
• Analysis of clinical factors associated with incomplete standard protocol 177Lu-DOTATATE treatment in neuroendocrine tumor patients

  2025influential citation
• Alpha radioligand therapy in neuroendocrine neoplasms: current landscape and spotlight on RYZ101.

  2025cites this paper
• Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [211At]At-anti-CA-IX Antibody (ATO-101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care

  2025cites this paper
• A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)

  2025influential citation
• The Treatment of Pancreatic Neuroendocrine Tumors - A Retrospective Single-Centre Study.

  2025cites this paper